Michael Robert Cooper
95 works · 4,696 citations · h-index 31
Top works
- Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
- Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
- Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
- Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
- Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer
- Effect of Suramin on Human Prostate Cancer Cells in Vitro
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
- A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
- Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
- Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
- Phase I study of phenylacetate administered twice daily to patients with cancer
- A Monoclonal IgM With Antibodylike Specificity for Phospholipids in a Patient With Lymphoma
- Human Toxic Neutrophils. III. Metabolic Characteristics
- A reassessment of Vulcanodon karibaensis Raath (Dinosauria:Saurischia) and the origin of the Sauropoda
- Cretaceous ammonite distributions and the opening of the South Atlantic
- Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
- Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents
- Use of Suramin in Treatment of Prostatic Carcinoma Refractory to Conventional Hormonal Manipulation
- A revision of the ornithischian dinosaur Kangnasaurus coetzeei Haughton, with a classification of the Ornithischia